- 1 Title: Evaluation of a training course for general practitioners within the Melanoma Multimedia Education
- 2 Programme of the Italian Melanoma Intergroup: study protocol
- 3
- 4 Authors:
- 5 Ignazio Stanganelli^{1,2}, Serena Magi¹, Lauro Bucchi³, Emanuele Crocetti³, Silvia Mancini³, Rosa Vattiato³, Stefano
- 6 Falcinelli⁴, Patrizia Re⁴, Davide Melandri⁵, Marco Brusasco⁶, Sara Gandini⁷, Fabio Falcini^{3,8} Federica Zamagni³
- 7 and the FAD MelaMEd Working Group
- 8
- 9 Affiliations:
- ¹Skin Cancer Unit, Romagna Cancer Institute, IRCCS IRST Istituto Romagnolo per lo Studio dei Tumori (IRST)
- 11 "Dino Amadori", Meldola, Forlì-Cesena, Italy
- 12 ²Division of Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy
- 13 ³Emilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei
- 14 Tumori (IRST) "Dino Amadori", Meldola, Forlì-Cesena, Italy
- 15 ⁴General Practitioner, district of Ravenna, AUSL Romagna, Ravenna, Italy
- ⁵Division of Dermatology Cesena/Forlì AUSL Romagna and Department of Medicine and Surgery, University
- 17 of Bologna, Italy
- 18 ⁶Dermatology Unit, ASST Santi Paolo e Carlo, Milan, Italy
- ¹⁹ ⁷Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
- 20 ⁸Cancer Prevention Unit, ASL Forlì, Forlì-Cesena, Italy
- 21 **Corresponding Author:**
- 22 Federica Zamagni
- 23 Emilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei
- 24 Tumori (IRST) "Dino Amadori", via Piero Maroncelli 40, 47014, Meldola (FC), Italy.
- 25 <u>federica.zamagni@irst.emr.it</u> Tel. +39 0543 739464
- 26 Key Words: NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
- 27 Melanoma, study protocol, multimedia education, diagnosis, prevention

28 Contributions:

- 29 Ignazio Stanganelli and Federica Zamagni conceived this article and drafted the manuscript.
- 30 Marco Brusasco, Lauro Bucchi, Emanuele Crocetti, Stefano Falcinelli, Fabio Falcini, Sara Gandini, Serena Magi,
- 31 Davide Melandri, Silvia Mancini, Patrizia Re, Rosa Vattiato revised the manuscript critically for important
- 32 intellectual content. All authors read and approved the final version of the manuscript.
- 33

34 Conflict of interest:

- 35 The authors declare no potential conflict of interest.
- 36

37 Ethics approval:

- 38 The study design complied with the Declaration of Helsinki ethical standards and was approved by the Ethics
- 39 Committee at the Romagna Cancer Institute (ID: IRST100.37; IRST identifier codes: L4P3037, wfn.27L4). The
- 40 study was approved by the Scientific Committee of the Italian Melanoma Intergroup (IMI).
- 41

42 Funding:

43 This work was partly supported thanks to the contribution of Ricerca Corrente by the Italian Ministry of Health

44 within the research line "Appropriateness, outcomes, drug value and organizational models for the continuity

45 of diagnostic-therapeutic pathways in oncology".

46 Abstract

47

The text discusses the role of general practitioners (GPs) in the prevention and early diagnosis of melanoma, a type of skin cancer. It highlights the need for GPs to be able to recognize suspicious skin lesions and refer patients to specialist dermatology centers. However, many GPs lack comprehensive training in diagnosing melanoma. The text mentions that various training courses have been conducted for GPs, but their impact on clinical practice has been limited.

53

The "MelaMEd Programme" is an e-learning course developed by the Italian Melanoma Intergroup (IMI). The program aims to provide GPs with comprehensive knowledge of melanoma prevention, diagnosis, and treatment. It includes an e-learning section and a dedicated platform called MelaMEd platform, which offers a multimedia atlas of melanoma.

58

59 The objective of the study is to evaluate the impact of the MelaMEd programme on GPs' diagnostic accuracy, 60 knowledge of melanoma, and management of suspicious lesions. The methodology involves administering 61 pre-training and post-training questionnaires to participants, assessing their diagnostic skills and evaluating 62 the training course's effectiveness.

63

The study aims to demonstrate the effectiveness of the MelaMEd programme in improving GPs' ability to recognize and manage melanoma. It also seeks to identify areas for improvement and recommend interventions to enhance diagnostic accuracy. The results will be analyzed statistically using descriptive, univariate, and multivariate analysis methods.

68 1. RATIONALE AND BACKGROUND INFORMATION

69 **1.1** The role of general practitioners in the prevention of melanoma

Several public information and education initiatives on self-skin surveillance have been carried out in many
 European nations throughout the years. Although very confusing, these initiatives have shown to significantly
 improve the time to diagnosis and survival from cutaneous melanoma.¹
 The primary prevention for skin malignancies, the clinical recognition of "suspicious melanoma" and the

identification of patients at risk of melanoma are the recommended strategies by Europe's Beating Cancer

75 Plan² and by Italian and international guidelines.³⁻⁶

76 According to these recommendations, general practitioners (GPs) and also paediatricians play an active role 77 in the referral pathway to the dermatology center. Being the natural "link" between patients and the 78 specialist reference centers, GPs must be able to recognize the skin lesions with clinical-morphological 79 characteristics that are consistent with early-stage melanoma. Additionally, they must be at least somewhat 80 familiar with the entire fundamental melanoma diagnostic-therapeutic pathway. In other words, their role is 81 mainly to select to high-risk population and perform a preliminary differential diagnosis, i.e., to select 82 patients susceptible to specialist diagnostic investigation. Nonetheless, many GPs lack of comprehensive 83 training in diagnosis, patient selection, and the diagnostic-therapeutic pathway for skin malignancies, 84 especially melanoma.

A recent review has collected the results of training courses for GPs on melanoma prevention. Interventions were heterogeneous and varied widely in the design and teaching methods, with live or online courses lasting from 5 minutes to 24 months.⁷ Whilst several initiatives have demonstrated significant improvements in melanoma knowledge and expertise, only a few studies have revealed positive changes in clinical practice through histological review.⁷

The adequate triage of skin lesions and the knowledge of the essential basis of the melanoma diagnostictherapeutic pathway allow an effective and efficient cooperation between GPs and specialist structures. According to the Italian Oncology Plan 2023-2027, the training of healthcare workers is considered "one of the best investments to guarantee high levels of performance" and "highly dynamic training interventions are recommended because they concern a continuously evolving sector with regards to care models,

95 technological innovations and the indispensable aspects of humanization and respect for the person".⁸ For 96 these reasons, the importance of multimedia technologies in education has been highlighted and the 97 widespread adoption of multimedia e-learning tools has been recommended. In Italy, the effect of formal 98 training on GP has been seldom evaluated and the impact of multimedia educational programme has never 99 been investigated.^{9,10}

100 **1.2** The "MelaMEd Programme" and the evaluation of its training impact

The Melanoma Multimedia Education (MelaMEd programme), one of the projects developed by the Italian Melanoma Intergroup (IMI), aims to provide physicians, mainly general practitioners, with a comprehensive understanding of the primary and secondary prevention of cutaneous melanoma and a broad overview of diagnostic and therapeutic procedures. The MelaMEd programme is hosted on a dedicated platform: an educational area which includes an e-learning section, with training courses accrediting Continuing Medical Education (CME) points.¹¹

107 This multimedia training course is aimed at building up, at a local level, a network between multidisciplinary 108 teams dealing with melanoma and healthcare workers. In particular, this training course has been 109 recommended to GPs, healthcare workers who are part of multidisciplinary melanoma teams and those 100 dealing, at a local level, with the management of patients with melanoma.

111 The MelaMEd programme provides the knowledge and experience that will enable participants to recognize 112 skin lesions requiring specialist dermatological consultation by applying validated methods. Recent scientific 113 evidence on the association between the trend of annual dermatology outpatient visit rates, skin biopsy rates 114 and melanoma incidence rates has demonstrated a limited selection of the population at risk and of suspicious melanoma by GPs.¹² This epidemiological data undoubtedly represents an important basis for the 115 implementation of specific training courses in the management of the diagnostic and therapeutic pathway 116 117 of melanoma. These premises also highlight the need to carry out an evaluation of the training course and 118 represent the rationale for this protocol.

119

120 **2. OBJECTIVE**

121 In the field of prevention, the expression *demonstration project* refers to projects in which a preventive tool

- of proven or accepted effectiveness (a dietary correction, a test for early diagnosis, etc.) is used in practice
- 123 with the aim to "show something and explain how it works".^{13,14}
- 124 The evaluation of these projects is essentially descriptive, and the MelaMEd programme has similar
- 125 characteristics. We plan to provide a teaching activity on a large scale to a potentially very large number of
- subjects, i.e. in a real rather than experimental situation.
- 127 To establish if and how this preventive strategy works, we have identified as a primary objective the MelaMEd
- 128 programme impact evaluation in terms of improvement in 1) diagnostic accuracy (recognition of suspicious
- lesion), 2) basic knowledge of the disease, and 3) management of suspicious lesion.
- 130 Our secondary objective is to gather useful information about how to enhance diagnostic accuracy and
- fundamental knowledge of melanoma. To address the first point, we will identify the areas in which the basic
- 132 knowledge of melanoma needs to be strengthened. To address the second point, we will assess the factors
- that may influence the accuracy of the diagnosis and recommend appropriate intervention.
- 134

135 3. STUDY DESIGN

136 **3.1 The MelaMEd programme**

The MelaMEd programme consists of a dedicated asynchronous e-learning course entitled "Early diagnosis and management of the therapeutic diagnostic pathway of melanoma". The asynchronous e-learning course includes, among the educational contents, a link to the MelaMEd platform, a website developed by IMI devoted to melanoma diagnosis and treatment. Direct access to the MelaMEd platform is possible from the asynchronous e-learning course.

The asynchronous e-learning course is free of charge and is delivered on behalf of the Federazione Nazionale degli Ordini dei Medici Chirurghi e degli Odontoiatri (FNOMCeO), a national association including all the Italian community of physician and dentists. The asynchronous e-learning course was activated on June 1st, 2022 and available until December 31, 2023.

146 The asynchronous e-learning course has included video presentations, with audio and visual information on

147 following topics: identification of risk groups; sun exposure pattern, photoprotection, melanoma diagnosis

using the mainly clinical Prediction Rules as ABCDE,^{15,16} EFG¹⁷ and the "Ugly Duckling" sign,^{18,19} histopathological diagnosis, surgical and medical therapy and finally interactive clinical cases in the various spectrums of melanoma progression with the related decision-making points.

151 For each topic, MelaMEd programme has an interactive function which allows the user to further explore 152 any aspect of the course material available in 'switching' modality with the MelaMEd platform.

The MelaMEd programme is a real revolution in the panorama of multimedia medical training, offering interaction and integration functions connecting the asynchronous e-learning format and the MelaMed platform.

156 **3.2 The MelaMEd platform**

The MelaMEd platform¹¹ is a vast virtual library, a multimedia atlas, free of charge, quick to access and easy to consult. Divided into fundamental chapters containing iconographic documentation of the clinical, dermoscopic and histological aspects of melanocytic pathology, the site is geared to raising awareness of the importance of identifying melanoma at an early stage. The MelaMEd platform also details surgical and medical treatments, stage and prognosis according to the latest guidelines accredited by Italian National Health Authority and by other European and international organizations.³⁻⁵

163 More specifically, the MelaMEd platform is divided into 10 chapters: epidemiology, risk factors, with 164 particular attention to ultraviolet radiation (chapters 1,2 and 3), clinical and differential diagnosis of 165 melanoma facilitated by the use of non-invasive cutaneous techniques (chapters 4, 5, 6 and 7), histological 166 diagnosis, medical and surgical therapy, staging, prognosis (chapters 8 and 9) and finally the most frequently 167 asked questions from patients, with related answers (chapter 10). Each multimedia chapter includes a combination of more than one media type such as text, symbols, pictures, audio, video, with the use of static 168 169 and dynamic images, as well as links to the most recent literature and the most updated official websites. 170 The MelaMEd platform's contents and descriptions are listed in Table 1.

171 **3.3 Phases of the Study**

Figure 1 illustrates an outline of the project. The project is divided into the following phases: 1) presentation of the project synopsis to the IMI centers, 2) the communication of participation in the project by the IMI centers 3) the administration of a pre-training questionnaire about the basic knowledge of the disease, the

recognition and management of suspicious lesions, 4) the administration of the training course, 5) the administration of a post-training questionnaire to those participants who have filled in the pre-training questionnaire, and 6) the comparison of pre and post-training answers to evaluate the training course impact.

179 **3.4 Inclusion and exclusion criteria**

All GPs, resident GPs and paediatricians of the healthcare system areas of the IMI centers are eligible. Participation is optional and, in case of participation, it is mandatory for participants to provide personal data processing consent, after reading and understanding the information on the processing of personal data according to EU Regulation 679/2016. There are no exclusion criteria.

184

185 4. METHODOLOGY

186 4.1 Pre-training and post-training questionnaire

The pre-training questionnaire is administered to eligible participants via Google Forms. To maximize the number of eligible people filling in the questionnaire, the coordinating centre and each participating centre arrange, in several calendar dates, a webinar to present the "MelaMEd project", inviting in the meantime the participants to fill in the questionnaire. The link to the questionnaire should, therefore, be sent via email in advance. We have chosen Google Forms because it allows us to easily fill in the questionnaire via smartphone. Each eligible person will also receive a numerical code, required in both the pre and post-training questionnaires. This code is used to match the answers during the analysis.

The questionnaire includes 7 multiple choice theoretical questions about the prevention of skin tumours and 10 images of skin tumours to be evaluated indicating 1) whether the lesion is benign or malignant, 2) one of 4 possible diagnoses, 3) whether the patient should be referred to a specialist for a medical consult and possible excision (Supplementary Table 1). The 10 images of pigmented lesions have been selected according to two criteria: (1) they are present in the MelaMEd platform, and (2) they reflect pigmented lesions commonly observed in general practice. These criteria allow us to assume that the participants' diagnostic skills observed in the questionnaire can be generalized to routine medical practice.

In the post-training questionnaire (Supplementary Table 1), the same questions as those included in the pre training one will be administered, together with 10 additional questions on the Likert scale for the training
 course global evaluation.²⁰

204 4.2 Questionnaire validation

Each question in the pre- and post-training questionnaires was extrapolated by recommendations by 205 international publications^{7,17,19,21,22} and by clinician guideline determinants by accredited by the National 206 Health Institute and European organizations.³⁻⁵ Furthermore, 20 people randomly chosen among those 207 208 eligible have been asked via Google Forms for feedback about the clarity and understandability of each 209 question. This methodology ensures that every respondent must, first of all, understand the question they are reading, strengthening the results.²³ Questions that has been evaluated include the 7 theoretical 210 211 questions and the 10 questions about the images, for a total of 17 questions. For the majority (14 out of 20) 212 of participants, all the 17 questions (100%) were asked in a clear and understandable way. For the remaining 213 6 participants, there were from 1 to 3, out of 17, not clear and understandable questions (Supplementary 214 Table 2). Furthermore, 9/17 questions were clear and understandable for 20 (100%) of participants, 6/17 215 questions for the 95%, and, lastly, 2/17 questions were clear and understandable for the 90% of participants. 216 These figures guarantee the strength of the results, once available.

217 **4.3 Consent to personal data processing**

218 The project handles participants' data, including name, last name, email address and workplace. An 219 information form will be issued to participants in accordance with EU Regulation 679/2016 regarding the 220 processing of personal data. At the beginning of the pre-training questionnaire, participants will be asked to 221 confirm that they have read and understood the information form above mentioned and whether they 222 authorize their data processing. Should a respondent decline authorization, the survey will instantly end, excluding the participant from the training course impact evaluation but not preventing his/her access to the 223 224 asynchronous e-learning course and to the MelaMEd platform. A notice is shown prior to the questionnaire 225 automatic closure, alerting participants in case they accidentally denied permission.

227 **5. STATISTICAL ANALYSIS**

- 228 Descriptive, univariate, and multivariate analysis of the questionnaire responses will be used to assess how
- the training program improved the participants' diagnostic performance.
- 230 The percentages of correct answers for the theoretical questions given before and after the training will be
- 231 compared.
- As for the answers to the questions relating to images, we will compare the percentages of correctly
- 233 diagnosed cases of benign or malignant melanoma, the percentages of right diagnoses, and the percentages
- 234 of referrals to dermatologists before and after training.
- 235 With reference to the answers to the global evaluation questions, the frequency distribution will be
- 236 calculated.
- 237 The Wilcoxon signed-ranks test will be used to compare the pre-training and post-training medians, and the
- 238 McNemar test for paired data will be used to compare the pre-training and post-training proportions. We
- 239 will use logistic regression models to investigate possible factors which might affect the accuracy of the
- 240 diagnosis.
- 241

242 6. DISSEMINATION

- 243 Results will be published via (inter)national peer-reviewed journals and the findings of the study will be
- communicated using a comprehensive dissemination strategy aimed at healthcare professionals, in
- 245 particular GPs, resident GPs and paediatricians.
- 246

247 Informed Consent Statement

There are no risks associated with this study. Individual patient consent was not required as anonymizeddata were used.

250

251 Data Availability Statement

252 The anonymized dataset used in this study is available on request from the corresponding author.

254 Acknowledgments

- 255 The European Institute of Oncology, Milan, Italy is partially supported by the Italian Ministry of Health with Ricerca
- 256 Corrente and 5×1,000 funds.

257

- 258 Working Group
- 259 The FAD MelaMEd Working Group includes:
- 260 Maria Antonietta Pizzichetta (Aviano, Trieste), Stefania Stucci, Marco Tucci (Bari), Vincenzo De Giorgi, Daniela Massi
- 261 (Firenze), Paola Ghiorzo, Cesare Massone, Enrica Tanda (Genova), Francesco de Rosa, Matelda Medri (Meldola), Roberto
- 262 Patuzzo (Milano), Corrado Caracò, Marco Palla (Napoli), Alessio Fabozzi (Padova), Mario Mandalà (Perugia), Riccardo
- 263 Marconcini (Pisa), Paolo Fava, Elena Marra, Pietro Quaglino, Simone Ribero (Torino) for the development of educational
- 264 contents.

266 References

- 267 1. AM Forsea. Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities.
- 268 Dermatol Pract Concept. 2020 Jul;10(3):e2020033.
- 269 2. Europe Beating Cancer Plan: website
- 270 https://health.ec.europa.eu/system/files/2022-02/eu cancer-plan en 0.pdf
- 271 3. Garbe C, Amaral T, Peris K, et al; European Dermatology Forum (EDF), the European Association of
- 272 Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer
- 273 (EORTC). European consensus- based interdisciplinary guideline for melanoma. Part 1: Diagnostics:
- 274 Update 2022. Eur J Cancer. 2022 Jul;170:236-255.
- 4. Garbe C, Amaral T, Peris K, et al; European Dermatology Forum (EDF), the European Association of
- 276 Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer
- 277 (EORTC). European consensus- based interdisciplinary guideline for melanoma. Part 2: Treatment -
- 278 Update 2022. Eur J Cancer. 2022 Jul;170:256-284.
- 279 5. Linee guida Aiom accreditated by ISS: website
- 280 https://www.iss.it/documents/20126/8403839/Addendum-LG_127_AIOM_Melanoma_ed2021
- 281 6. Linee Guida Siapec accreditated by ISS Società Italiana di Anatomia Patologica: website
- 282 https://www.siapec.it/2022/07/18/lg-snlg-lesioni-melanocitarie/
- 283 7. AE Brown, M Najmi, T Duke et al. Skin Cancer Education Interventions for Primary Care Providers: A
- 284 Scoping Review. J Gen Intern Med. 2022 Jul;37(9):2267-2279.
- 285 8. PON: documento pdf Piano Oncologico Nazionale: documento di pianificazione e indirizzo per la
- 286 prevenzione e il contrasto del cancro 2023-2027: website
- 287 https://www.salute.gov.it/imgs/C_17_pubblicazioni_3291_allegato.pdf
- 288 9. Carli P, De Giorgi V, Crocetti E, et al. Diagnostic and referral accuracy of family doctors in melanoma
- screening: effect of a short formal training. Eur J Cancer Prev 2005;14:51–5.
- 290 10. Argenziano G, Puig S, Zalaudek I et al. Dermoscopy improves accuracy of primary care physicians to
- triage lesions suggestive of skin cancer. J Clin Oncol. 2006 Apr 20;24(12):1877-82.
- 292 11. MelaMEd platform: website https://www.imi-melamed.it/

- 293 12. L Bucchi, S Mancini, F Zamagni et al. Patient presentation, skin biopsy utilization and cutaneous
- 294 malignant melanoma incidence and mortality in northern Italy: Trends and correlations. J Eur Acad

295 Dermatol Venereol. 2022 Sep 30.

- 13. Grewal R, Jones R, Peters J, et al. Providing telemedicine services to persons living with HIV in an urban
- 297 community: a demonstration project. AIDS Care. 2023 Apr 3:1-10.
- 14. Mai V, Flood A, Peters U, et al. Dietary fibre and risk of colorectal cancer in the Breast Cancer
- 299 Detection Demonstration Project (BCDDP) follow-up cohort. Int J Epidemiol. 2003 Apr;32(2):234-9.
- 300 15. R J Friedman, D S Rigel, A W Kopf. Early detection of malignant melanoma: the role of physician
- 301 examination and self-examination of the skin. CA Cancer J Clin. 1985 May-Jun;35(3):130-51.).
- 302 16. Arrington E, Clyne B, Wesseling N, et al. Diagnosing malignant melanoma in ambulatory care: a
- 303 systematic review of clinical prediction rules. BMJ Open. 2017 Mar 6;7(3).
- Kelly JW, Chamberlain AJ, Staples MP, McAvoy B. Nodular melanoma. No longer as simple as ABC. Aust
 Fam Physician 2003 Sep;32(9):706-9.
- 306 18. JJ Grob, J Bonerandi. The 'ugly duckling' sign: identification of the common characteristics of nevi in an
 307 individual as a basis for melanoma screening. Arch Dermatol. 1998 Jan;134(1):103-4.
- 308 19. Gaudy-Marqueste C, Wazaefi Y, Bruneu Y, et al. Ugly Duckling Sign as a Major Factor of Efficiency in
 309 Melanoma Detection. JAMA Dermatol. 2017 Apr 1;153(4):279-284.
- 20. Batterton, K. A., & Hale, K. N. (2017). The Likert Scale What It Is and How To Use It. Phalanx, 50(2), 32–
- 311 39.
- 312 21. Grange F, Woronoff AS, Bera R, et al. Efficacy of a general practitioner training campaign for early
- detection of melanoma in France. Br J Dermatol. 2014;170(1):123-129.
- 22. Anders MP, Fengler S, Volkmer B, Greinert R, Breitbart EW. Nationwide skin cancer screening in
- 315 Germany: Evaluation of the training program. Int J Dermatol. 2017;56(10):1046-1051.
- 23. Tourangeau R, Rips LJ, Rasinski K. The Psychology of Survey Response (Book). Cambridge. U.K.:
- 317 Cambridge University Press, 2000. ISBN 0-5215-7246-0.
- 318
- 319

320 Tables and figures

321 **Table 1.** Number, name and description of the chapters included in the MelaMEd platform

Number	Name	Description
1	Epidemiology	Epidemiology of melanoma in terms of incidence, mortality and survival that reports the main references at international and national level
2	Risk factors	Comprehensive review of following mainly risk features: genetic, phototypes, melanocytic nevi, ABCDE and EFG rules, ugly duckling sign
3	Sun exposure, mole and the melanoma risk	Description of endogenous, or inherited, risk factors, and exogenous, or independent, risk factors. Photo-protection and tips to ensure correct sun exposure
4	Diagnosing melanoma	Explanation of self-examination importance and of the GP and dermatologist role
5	Clinical diagnosis of melanoma	Description and iconographic documentation of the different clinical spectrum of melanoma and special clinical forms related to degree of pigmentation and/or location
6	Clinical differential diagnosis	Description and iconographic documentation of the different clinical spectrum of benign melanocytic lesions (nevi) and benign or malignant non-melanocytic lesions
7	Early diagnosis with instrumental assessment	Dermoscopy analysis and other non-invasive instrumental methods such as sequential dermoscopy, total body photography and confocal microscopy. Dermoscopical and histopathological correlations. Description and iconographic documentation of the clinical and dermoscopical melanocytic nevi, melanoma and benign or malignant non- melanocytic lesions
8	Histological diagnosis	Histopathological and molecular diagnosis of melanoma and melanocytic lesions recommended by WHO Classification of Skin Tumours 4th edition
9	Surgery, staging, prognosis and treatment	Comprehensive review of surgical treatment, staging, prognosis, follow-up and treatment topics
10	Questions patients ask	List of the most frequently asked questions from patients, with the related answers

323 Figure 1. Name and description of the study phases

1-Project presentation	• The project synopsis is presented to the IMI centers
2-Enrollment	 Centers communicate their willingness to participate in the project The proponent center gets in touch with each participating center
3-Pre-training	 Administration of a pre-training questionnaire about the basic knowledge of the disease, the recognition and management of suspicious lesions
4-Training	• Participants are given a period of time to follow the training courses
5-Post-training	• Participants are given access to the post-training survey
6-Analyses	 Matching of the pre-training and post-training answers Statistical analyses

326 Supplementary material

327 **Supplementary Table 1.** Question and answers of the pre-training and post-training questionnaires. The

328 right answer is underlined

Question number	Question text	Multiple choice answer
	Consent and demogra	phic questions
1	In accordance with EU Regulation 679/2016 regarding personal data protection, do you consent to the processing of your personal data?	a) Yes b) No
2	Select your job title	a) General Practitionerb) Resident General Practitionerc) Paediatrician
3	What age group do you belong to?	a) <40 b) 40-60 c) >60
	Theoretical q	
1*	Which of the following is a risk factor for melanoma?	 a) <u>Ultraviolet radiation</u> b) Cigarette smoke c) Consumption of red meat d) Alcohol abuse
2*	What is needed for a complete visual examination of the skin?	 a) Evaluation only of the suspected neoformation reported by the patient b) Live evaluation of the entire skin area in dim light c) Live evaluation of the entire skin area in optimal lighting conditions and with the use of a magnifying glass d) Referral to the specialist reference centre
3*	What does the ABCDE acronym for the recognition of a suspected melanoma mean?	 a) Asymmetry, Regular edges, Homogeneous colour, Dimensions <2 mm, Empathy b) Asymmetry, Irregular edges, Homogeneous colour, Dimensions <5 mm, Static evolution c) Asymmetry, Irregular edges, Uneven colour, Dimensions >6 mm, rapid Evolution d) Asymmetry, Irregular edges, Homogeneous color, Small dimensions, Entropy e) I don't know the ABCDE acronym
4*	What does the EFG rule coined by Australian dermatologists for the recognition of suspected nodular melanoma mean?	 a) Erithema, Firm, Ground b) <u>Elevation, Firm, Growth</u> c) Evolution, Figure, Great dimension d) Extension, Family history, Great dimension e) I don't know the EFG rule
5*	What is meant by the "ugly duckling" sign for recognizing a suspected melanoma?	 a) Homogeneous nevus equal to other nevus in shape and color b) Nevus regular compared to other nevus c) Moriform congenital nevus d) <u>Different nevus that "stands out" compared</u> <u>to other nevus due to its shape, color</u> <u>and/or rapid evolution</u>

		e)	I don't know the sign of the "ugly duckling"
6*	Which of the following statements about	a)	Dermoscopy is a non-invasive technique
-	dermoscopy is true?		that allows the in vivo evaluation of skin
			colors and structures not visible to the
			naked eye
		b)	Dermoscopy is a non-invasive technique
		5,	that uses a laser beam with a near-infrared
			wavelength (830 nm), to evaluate the cells
			of the superficial layer of the skin at a depth
			of approximately 100-200 µm
		c)	Dermoscopy is an incisional biopsy specific
			for melanocytic lesions
		۹)	-
		d)	Dermoscopy can replace histological examination
7*	Which of the following statements about		
7*	Which of the following statements about	a)	It indicates the degree of invasion of the
	Breslow thickness is true?		skin. It is divided into 5 levels based on the
			degree of infiltration: from I (melanoma in
			situ) to V (infiltration of the entire dermis
			up to the adipose tissue)
		b)	
			from the granular layer of the skin (or from
			the base of the ulcer if the lesion is
			ulcerated) to the point of maximum
			infiltration into the dermis. It is measured in
			<u>mm</u>
		c)	It indicates whether the melanoma is in the
			horizontal or vertical histological phase
		d)	It indicates the depth of tumor-infiltrating
			lymphocytes (TILs)
1*	Ima	- -	Donign
Τ.	Consider the following pigmented lesion, indicate if it is:	a)	Benign Malignant
	indicate in it is:	b)	Malignant
		c)	I don't know
	Would you refer the patient to a	a)	Yes
	dermatologist?	b)	No
	Which is your diagnosis?	a)	Common Nevus
		b)	Atypical Nevus
		c)	Melanoma
		d)	Seborrheic Keratosis
2*	Consider the following pigmented lesion,	a)	Benign
	indicate if it is:	b)	Malignant
		c)	I don't know
	Would you refer the patient to a	a)	Yes
	dermatologist?	b)	No
	Which is your diagnosis?	a)	Seborrheic Keratosis
		b)	Common Nevus
		c)	Congenital Nevus
		d)	Melanoma
3*	Consider the following pigmented lesion,	a)	Benign
	indicate if it is:	b)	Malignant
		c)	I don't know

	Would you refer the patient to a	a) Yes
	dermatologist?	b) No
	Which is your diagnosis?	a) <u>Seborrheic Keratosis</u>
		b) Common Nevus
		c) Atypical Nevus
		d) Melanoma
4*	Consider the following pigmented lesion,	a) Benign
•	indicate if it is:	b) Malignant
		c) I don't know
	Would you refer the patient to a	a) Yes
	dermatologist?	b) No
	Which is your diagnosis?	a) Seborrheic Keratosis
	Which is your diagnosis:	b) Common Nevus
		c) Congenital Nevus
		d) Melanoma
5*	Consider the following pigmented lesion,	a) Benign
5	indicate if it is:	b) Malignant
		c) I don't know
	Would you refer the patient to a	a) Yes
	dermatologist?	b) No
	Which is your diagnosis?	a) Congenital Nevus
		 b) <u>Melanoma</u> c) Seborrheic Keratosis
		d) Basal cell carcinoma
6*	Consider the following nigmented locion	
0	Consider the following pigmented lesion, indicate if it is:	a) Benign b) Malignant
	indicate in it is.	, C
	Mould you refer the nationt to a	
	Would you refer the patient to a	a) Yes
	dermatologist?	b) No
	Which is your diagnosis?	a) <u>Melanocytic Nevus</u>
		b) Basal cell carcinoma
		c) Melanoma
		d) Seborrheic Keratosis
7*	Consider the following pigmented lesion,	a) Benign
	indicate if it is:	b) Malignant
		c) I don't know
	Would you refer the patient to a	a) Yes
	dermatologist?	b) No
	Which is your diagnosis?	a) Atypical Nevus
		b) <u>Congenital Nevus</u>
		c) Melanoma
• *		a) Basal cell carcinoma
8*	Consider the following pigmented lesion,	a) Benign
	indicate if it is:	b) Malignant
		c) I don't know
	Would you refer the patient to a	a) Yes
	dermatologist?	b) No
	Which is your diagnosis?	a) Melanocytic Nevus
		b) Angioma
		c) <u>Melanoma</u>
		d) Basal Cell Carcinoma

0*	Consider the following migrocented losis	-	Donign
9*	Consider the following pigmented lesion,	a)	Benign
	indicate if it is:	b)	Malignant
		c)	I don't know
	Would you refer the patient to a	a)	Yes
	dermatologist?	b)	No
	Which is your diagnosis?	a)	Solar Lentigo
		b)	Seborrheic Keratosis
		c)	Congenital Nevus
		d)	<u>Malignant Lentigo</u>
10*	Consider the following pigmented lesion,	a)	Benign
	indicate if it is:	b)	Malignant
		c)	I don't know
	Would you refer the patient to a	a)	Yes
	dermatologist?	b)	No
	Which is your diagnosis?	a)	Seborrheic Keratosis
		b)	Basal Cell Carcinoma
		c)	Congenital Nevus
		d)	Melanoma
	Global evaluation	,	
1*	How confident do you feel in giving patients	a)	Absolutely not confident
-	information on the primary prevention of skin	b)	Not confident
	cancer?	c)	Don't know
		d)	Confident
		e)	Absolutely confident
2*	Llow confident de vou feel in informing the		•
Ζ.,	How confident do you feel in informing the	a)	Absolutely not confident
	patient about the skin self-examination?	b)	Not confident
		c)	Don't know
		d)	Confident
		e)	Absolutely confident
3*	How confident do you feel in making a	a)	Absolutely not confident
	diagnosis of a suspected melanoma?	b)	Not confident
		c)	Don't know
		d)	Confident
		e)	Absolutely confident
4**	Do you think MelaMEd has improved your	a)	Absolutely disagree
	ability to recognize patients at high risk of	b)	Disagree
	melanoma?	c)	Don't know
		d)	Agree
		e)	Absolutely agree
5**	Do you think MelaMEd has improved your	a)	Absolutely disagree
	ability to distinguish melanoma from benign	b)	Disagree
	lesions?	c)	Don't know
		d)	Agree
		e)	Absolutely agree
6**	Do you think MelaMEd has improved your	a)	Absolutely disagree
0	knowledge in skin cancer management?	b)	Disagree
		c)	Don't know
		d)	Agree
7**		e)	Absolutely agree
7**	Do you prefer multimedia training based on	a)	Absolutely disagree
	the MelaMEd model to traditional live	b)	Disagree
	training?	c)	Don't know

		d) Agree
		e) Absolutely agree
8**	Do you think that the active participation of	a) Absolutely disagree
	GPs, resident GPs and paediatricians can	b) Disagree
	improve the early diagnosis of melanoma?	c) Don't know
		d) Agree
		e) Absolutely agree
9**	Would you be interested in attending a	a) Yes
	dermoscopy course?	b) No
10**	Would you like to receive additional	a) Yes
	information about melanoma on a regular	b) No
	basis?	

GP, General practitioner;

- *, question present both in pre-training and post-training questionnaire
- **, question present only in the post-training questionnaire

- Supplementary Table 2. Distribution of the number of clear and understandable questions from the pre
- and post-training questionnaire. Questions that has been evaluated include the 7 theoretical questions and
- the 10 questions about the images, for a total of 17 questions.

Participants	Clear and understandable questions N(%)	Not clear and understandable questions N(%)
14	17 (100)	0 (0)
3	16 (94)	1 (6)
2	15 (88)	2 (12)
1	14 (82)	3 (18)